Reamputation risk and mortality after lower-limb amputation in patients with diabetes: predictors, effects of antidiabetic medications and temporal trends
Diabetes remains to be associated with reduced reamputation-free survival; an association that is independent of increased prevalence of comorbidities in our data. Although reamputation risk has increased in recent years, overall survival has improved in patients with diabetes. Metformin usage is associated with improved reamputation-free survival while our limited data suggest increased risk of reamputation but safety with respect to mortality in patients treated with SGLT2i. Further studies are warranted to evaluate the effect of SGLT2i therapy on outcome in patients undergoing LLA.
Authors
- Matteo Landolfo (ORCID: https://orcid.org/0000-0002-2087-2573)
- Josef Klocker (ORCID: https://orcid.org/0000-0002-0585-3657)
- Faisal Aziz
- Bernhard Radlinger (ORCID: https://orcid.org/0000-0002-7034-8155)
- Susanne Kaser (ORCID: https://orcid.org/0000-0003-2524-5218)
- Lena Kopp (ORCID: https://orcid.org/0000-0002-6767-4101)
- Jana Blasinger
- Verena Streitberger
- Nicolas Köllenberger
- Georg Göbel
- Elena Bifano
- Harald Sourij
Institutions
- Marche Polytechnic University (IT)
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Medical University of Graz (AT)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1186/s12933-026-03145-9
- Primary Topic
- Diabetic Foot Ulcer Assessment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00